Can I Get Compounded Retatrutide Now?

Compounding pharmacies in the United States operate under FDA regulations that require the active pharmaceutical ingredient (API) to have an established safety profile, typically through FDA approval of at least one finished drug product containing that ingredient. Since retatrutide has not received FDA approval for any indication, it cannot be legally compounded by any 503A (patient-specific) or 503B (outsourcing facility) pharmacy.

This is a critical distinction from semaglutide and tirzepatide, which can be compounded because both have FDA-approved reference products (Ozempic/Wegovy for semaglutide, Mounjaro/Zepbound for tirzepatide). The existence of an FDA-approved product establishes the safety and regulatory framework that allows compounding pharmacies to prepare versions of the medication.

The Phase 2 results for retatrutide have generated significant public interest and, unfortunately, a market for unregulated products. Some online vendors, peptide suppliers, and overseas pharmacies claim to sell retatrutide for research purposes, personal use, or as a compounded medication.

These products are not manufactured under FDA oversight, are not tested for purity or potency, and may contain incorrect doses, contaminants, or entirely different substances than advertised. Using such products carries serious health risks including adverse reactions from unknown ingredients, incorrect dosing leading to dangerous side effects, and potential interactions with other medications.

The label "for research use only" is often used as a legal shield by vendors selling to individual consumers. This does not make the product safe, legal for human use, or equivalent to the pharmaceutical-grade retatrutide used in Eli Lilly's clinical trials.

Compounded retatrutide could become available only after the FDA approves retatrutide as a finished drug product. Based on the current development timeline, this is unlikely before 2027-2028 at the earliest. Even after approval, compounding would only be permitted under specific circumstances:

Drug shortage: If the brand-name product experiences supply shortages (as happened with semaglutide and tirzepatide), the FDA may add it to the shortage list, allowing compounding pharmacies to produce versions.

Patient-specific needs: 503A pharmacies can compound for individual patients who have a specific medical need for a formulation not commercially available (e.g., different concentration, preservative-free).

The path from FDA approval to compounded availability depends on market dynamics, supply chain capacity, and regulatory decisions. For semaglutide and tirzepatide, compounding became widespread largely due to extended supply shortages of the brand-name products.

Two FDA-approved GLP-1 medications are available today as brand-name products. Compounded preparations of these medications are also dispensed by licensed compounding pharmacies:

Semaglutide: Available as Wegovy® (weight management) and Ozempic® (type 2 diabetes), both FDA-approved branded products from Novo Nordisk. Compounded semaglutide is also dispensed by licensed compounding pharmacies in vials at concentrations from 1 to 5 mg/mL.

Tirzepatide: Available as Zepbound® (weight management) and Mounjaro® (type 2 diabetes), both FDA-approved branded products from Eli Lilly. Compounded tirzepatide is also dispensed by licensed compounding pharmacies in vials at concentrations from 5 to 30 mg/mL.

The branded products are FDA-approved, well-studied, and legally available. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Consult with a licensed healthcare provider to determine which option is appropriate for your situation.